Safety and Immunogenicity of a Live Attenuated Hepatitis A Virus Vaccine in Seronegative Volunteers

Seronegative adults were enrolled in a dose-escalating study of a live attenuated hepatitis A virus (HAV) vaccine that was prepared from the F' variant of HAV stain CR326F. They were injected subcutaneously with 10 4.1 , 10 5.2 , 10 6.1 , or 10 7.3 TCID 50 of HAV vaccine (n=40) or with placebo (n=12) and were followed for 6 months